Trilogy Global Advisors’s Celgene Corp CELG Stock Holding History

Trilogy Global Advisors’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-201,184	Closed	-$26.1M	–	73
2017 Q2	$26.1M	Buy	+201,184	New	+$24.7M	0.88%	40

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Trilogy Global Advisors's CELG Position: Q3 2017 in Review

Trilogy Global Advisors sold out of Celgene Corp (CELG) in Q3 2017, closing a stake of 201,184 shares — an estimated $26.1M sold.

Trilogy Global Advisors first reported a position in CELG in Q2 2017 and held it in 1 quarter. The position peaked at $26.1M in Q2 2017. 1,484 funds tracked by Wall St. Rank hold CELG as of Q3 2017.

Trilogy Global Advisors reported no remaining Celgene Corp position as of Q3 2017 after selling out during the quarter.
Trilogy Global Advisors sold 201,184 Celgene Corp shares in Q3 2017, an estimated $26.1M.
Trilogy Global Advisors first reported a position in Celgene Corp in Q2 2017 and held it in 1 quarter.
Trilogy Global Advisors's Celgene Corp position peaked at $26.1M in Q2 2017.
1,484 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2017.

Based on Trilogy Global Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.